Progyny (NASDAQ:PGNY) CFO Sells $64,170.00 in Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 2,139 shares of the business’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $30.00, for a total transaction of $64,170.00. Following the transaction, the chief financial officer directly owned 70,314 shares in the company, valued at $2,109,420. This trade represents a 2.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Price Performance

NASDAQ:PGNY opened at $34.84 on Monday. Progyny, Inc. has a one year low of $16.10 and a one year high of $35.50. The company has a fifty day moving average price of $27.45 and a 200 day moving average price of $24.59. The stock has a market cap of $2.67 billion, a P/E ratio of 31.96, a PEG ratio of 1.83 and a beta of 0.97.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The company had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. During the same period last year, the business posted $0.15 EPS. The business’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, equities research analysts anticipate that Progyny, Inc. will post 1.25 EPS for the current year.

Key Stories Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
• Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
• Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
• Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Zacks Research downgraded Progyny from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 19th. Cantor Fitzgerald boosted their price target on Progyny from $31.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday. Leerink Partners upped their price target on Progyny from $37.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday. JPMorgan Chase & Co. upped their price target on Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, August 21st. Finally, Jefferies Financial Group set a $33.00 price objective on Progyny in a research report on Tuesday, September 8th. Eleven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.92.

Institutional Trading of Progyny

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Progyny in the 2nd quarter valued at $334,426,000. Bank of America Corp DE boosted its stake in Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after purchasing an additional 511,609 shares in the last quarter. William Blair Investment Management LLC boosted its stake in Progyny by 10.7% in the third quarter. William Blair Investment Management LLC now owns 645,130 shares of the company’s stock worth $16,251,000 after purchasing an additional 62,178 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Progyny by 16.4% during the first quarter. Principal Financial Group Inc. now owns 554,916 shares of the company’s stock worth $9,422,000 after purchasing an additional 78,198 shares during the last quarter. Finally, Danske Bank A S bought a new stake in shares of Progyny during the second quarter worth $15,243,000. 94.93% of the stock is currently owned by institutional investors.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.